Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
121 hedge funds and large institutions have $164M invested in Achillion Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 27 closing their positions.
584% more call options, than puts
Call options by funds: $1.17M | Put options by funds: $171K
0% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 40
12% less funds holding
Funds holding: 137 → 121 (-16)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
58% less capital invested
Capital invested by funds: $394M → $164M (-$230M)
59% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCO
MAK Capital One
New York
|
+$9.17M |
| 2 |
AC
Armistice Capital
New York
|
+$6.5M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.71M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.71M |
| 5 |
Two Sigma Investments
New York
|
+$3.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.75M |
| 3 |
NC
Nexthera Capital
New York
|
-$5.83M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.76M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$4.71M |
ACHN Hedge Fund Activity: Q4 2018 in Review
121 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2018, worth a combined $164M — down 58% from $394M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ACHN and 11 opened new positions — a net loss of 16 holders — while 40 trimmed existing stakes and 40 added.
The largest buyer was MAK Capital One, adding an estimated $9.17M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.5M sold.
- 121 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2018, down from 137 in Q3 2018.
- Funds reported $164M of Achillion Pharmaceuticals stock for Q4 2018, down 58% quarter-over-quarter.
- 11 funds opened new Achillion Pharmaceuticals positions in Q4 2018 and 27 closed out, a net change of -16 holders.
- The largest Achillion Pharmaceuticals buyer in Q4 2018 was MAK Capital One, an estimated $9.17M added.
- The largest Achillion Pharmaceuticals seller in Q4 2018 was T. Rowe Price Associates, an estimated $16.5M sold.
Based on aggregated 13F filings for Q4 2018.